Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01193153 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

A Phase 3 study of Schizoaffective Disorder, sponsored by Janssen Scientific Affairs.

Completed
Registry status
Phase 3
Development phase
667
Enrollment target
20
Study locations

NCT01193153 is a Phase 3 study of Schizoaffective Disorder that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 667 participants, above the 193-participant average among 81 other Schizoaffective Disorder trials with a reported enrollment target (246% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01193153, a Phase 3 study of Schizoaffective Disorder, has completed, sponsored by Janssen Scientific Affairs.

COMPLETED
Registry status
Phase 3
Development phase
667 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the efficacy of paliperidone palmitate compared with placebo in the delay of relapse of the symptoms of schizoaffective disorder. This study will also assess the safety and tolerability of paliperidone palmitate in patients with schizoaffective disorder.

Conditions Studied

Schizoaffective Disorder

Interventions

  • DRUG Placebo
  • DRUG paliperidone palmitate

Study Locations (20)

California

  • - Garden Grove
  • - Oakland
  • - Oceanside
  • - Pico Rivera
  • - Riverside
  • - San Diego
  • - Torrance

Florida

  • - Hollywood
  • - Maitland
  • - North Miami
  • - Tampa

Georgia

  • - Atlanta
  • - Marietta

New York

  • - Cedarhurst
  • - Staten Island

Colorado

  • - Denver

Illinois

  • - Schamburg

Kansas

  • - Wichita

Mississippi

  • - Flowood

Trial Details

FieldValue
Enrollment Target 667 participants
Start Date 2010-09
Est. Completion 2013-10
Phase Phase 3

Sponsor

Janssen Scientific Affairs

37 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01193153

The ClinicalTrials.gov registry entry for NCT01193153 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 667 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 193-participant average among 81 other Schizoaffective Disorder trials with a reported enrollment target (246% higher). The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizoaffective Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01193153 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT01193153 about?

NCT01193153 is a clinical study titled "A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder". This study will evaluate the efficacy of paliperidone palmitate compared with placebo in the delay of relapse of the symptoms of schizoaffective disorder. This study will also assess the safety and tolerability of paliperidone palmitate in patients with schizoaffective disorder.

What is the current status of trial NCT01193153?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 667 participants. The study started on 2010-09. Estimated completion is 2013-10.

What conditions does trial NCT01193153 study?

This clinical trial studies the following conditions: Schizoaffective Disorder.

What interventions are being tested in trial NCT01193153?

The interventions under investigation include: Placebo (DRUG), paliperidone palmitate (DRUG).

Who is sponsoring clinical trial NCT01193153?

This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01193153 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizoaffective Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizoaffective Disorder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.